Tuesday December 18, 2012 0 comments
FORT COLLINS - CHD Bioscience Inc. has signed a master research and development agreement with Colorado State University, the company announced.
The agreement outlines the working relationship between CHD and CSU researchers and contains terms for licensing potential future intellectual property that may come from the relationship.
"This research agreement will help facilitate further collaborative work with CSU's Mycobacterium Research Lab group, as well as other infectious research faculty who can utilize CHD technology to find new ways of treating some of the most prolific infectious diseases in industrialized and developing countries," said Mike Handley, CHD's CEO.
"We look forward to collaborating with some of the top researchers in the field of infectious disease," said Ed Neas, CHD's chief technology officer.
CHD said it intends to initiate work with CSU faculty in the areas of chemistry enhancement, mycobacterium treatment, cutaneous and pulmonary infections.
"This type of collaborative research relationship is a critical link in moving innovation from the laboratory into real products and services that can directly address the growing needs in the infectious disease field," said Bill Farland, CSU vice president for research.
For more information, visit www.chdbioscience.com.